SK7222000A3 - Combination of an aldose reductase inhibitor and a glycogen phosphorylase inhibitor - Google Patents

Combination of an aldose reductase inhibitor and a glycogen phosphorylase inhibitor Download PDF

Info

Publication number
SK7222000A3
SK7222000A3 SK722-2000A SK7222000A SK7222000A3 SK 7222000 A3 SK7222000 A3 SK 7222000A3 SK 7222000 A SK7222000 A SK 7222000A SK 7222000 A3 SK7222000 A3 SK 7222000A3
Authority
SK
Slovakia
Prior art keywords
chloro
indole
carboxylic acid
amide
benzyl
Prior art date
Application number
SK722-2000A
Other languages
English (en)
Slovak (sk)
Inventor
Banavara Lakshman Mylari
Dennis Jay Hoover
Bernard Hulin
Judith Lee Treadway
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of SK7222000A3 publication Critical patent/SK7222000A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
SK722-2000A 1997-11-21 1998-11-02 Combination of an aldose reductase inhibitor and a glycogen phosphorylase inhibitor SK7222000A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6636597P 1997-11-21 1997-11-21
PCT/IB1998/001752 WO1999026659A1 (en) 1997-11-21 1998-11-02 Combination of an aldose reductase inhibitor and a glycogen phosphorylase inhibitor

Publications (1)

Publication Number Publication Date
SK7222000A3 true SK7222000A3 (en) 2001-09-11

Family

ID=22069038

Family Applications (1)

Application Number Title Priority Date Filing Date
SK722-2000A SK7222000A3 (en) 1997-11-21 1998-11-02 Combination of an aldose reductase inhibitor and a glycogen phosphorylase inhibitor

Country Status (38)

Country Link
EP (1) EP1032424B9 (uk)
JP (1) JP2002504478A (uk)
KR (2) KR20010032304A (uk)
CN (1) CN1279617A (uk)
AP (1) AP911A (uk)
AR (1) AR016423A1 (uk)
AT (1) ATE205403T1 (uk)
AU (1) AU733304B2 (uk)
BG (1) BG104435A (uk)
BR (1) BR9814698A (uk)
CA (1) CA2310069A1 (uk)
DE (1) DE69801680T2 (uk)
DK (1) DK1032424T3 (uk)
DZ (1) DZ2656A1 (uk)
EA (1) EA002365B1 (uk)
ES (1) ES2161548T3 (uk)
GR (1) GR3037071T3 (uk)
GT (1) GT199800166A (uk)
HR (1) HRP20000327A2 (uk)
HU (1) HUP0100272A3 (uk)
ID (1) ID24524A (uk)
IL (1) IL135713A0 (uk)
IS (1) IS5453A (uk)
MA (1) MA26568A1 (uk)
NO (1) NO20002164L (uk)
OA (1) OA11379A (uk)
PA (1) PA8462301A1 (uk)
PE (1) PE135399A1 (uk)
PL (1) PL340643A1 (uk)
PT (1) PT1032424E (uk)
SK (1) SK7222000A3 (uk)
TN (1) TNSN98211A1 (uk)
TR (1) TR200001451T2 (uk)
UA (1) UA57811C2 (uk)
UY (1) UY25258A1 (uk)
WO (1) WO1999026659A1 (uk)
YU (1) YU30700A (uk)
ZA (1) ZA9810636B (uk)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000047206A1 (en) * 1999-02-12 2000-08-17 Novo Nordisk A/S Use of pyrrolidine derivatives for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity or appetite regulation
JP2003520226A (ja) 2000-01-21 2003-07-02 ノバルティス アクチエンゲゼルシャフト ジペプチジルペプチダーゼ−ｉｖ阻害剤および抗糖尿病薬剤を含む組合せ物
CO5271699A1 (es) * 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
US6570013B2 (en) 2000-02-16 2003-05-27 Pfizer Inc Salts of zopolrestat
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
IL144507A0 (en) * 2000-07-31 2002-05-23 Pfizer Prod Inc Use of glycogen phosphorylase inhibitors to inhibit tumor growth
WO2002098429A1 (en) * 2001-06-07 2002-12-12 Pfizer Products Inc. Ethanolamine, diethanolamine or triethanolamine salt of zopolrestat
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
CA2392486A1 (en) 2002-07-05 2002-12-08 Duchesnay Inc. Pharmaceutical dosage form bearing pregnancy-friendly indicia
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
US7317109B2 (en) 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
WO2005047297A1 (en) 2003-11-12 2005-05-26 Phenomix Corporation Heterocyclic boronic acid compounds
US7576121B2 (en) 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7767828B2 (en) 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7786163B2 (en) 2004-07-12 2010-08-31 Forest Laboratories Holdings Limited (BM) Constrained cyano compounds
WO2006055435A1 (en) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
US7365061B2 (en) 2004-11-15 2008-04-29 Bristol-Myers Squibb Company 2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006055462A1 (en) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7214704B2 (en) 2004-11-15 2007-05-08 Bristol-Myers Squibb Company 2-Amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US20060235028A1 (en) 2005-04-14 2006-10-19 Li James J Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
US7825139B2 (en) 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
PE20070458A1 (es) 2005-09-14 2007-07-05 Takeda Pharmaceutical Composicion farmaceutica que comprende 2-[[6-(3r)-3-amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2h)-pirimidinil]metil]-benzonitrilo como inhibidor de dipeptidil peptidasa
EP2046753A2 (en) 2006-07-06 2009-04-15 Brystol-Myers Squibb Company Pyridone/hydroxypyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors
US7727978B2 (en) 2006-08-24 2010-06-01 Bristol-Myers Squibb Company Cyclic 11-beta hydroxysteroid dehydrogenase type I inhibitors
CN101687873A (zh) 2007-04-17 2010-03-31 百时美施贵宝公司 具有稠合杂环的11β-羟基类固醇Ⅰ型脱氢酶抑制剂
PE20090222A1 (es) 2007-05-04 2009-03-27 Bristol Myers Squibb Co Compuestos [6,6] y [6,7]-biciclicos como agonistas del receptor acoplado a la proteina g gpr119
ES2388315T3 (es) 2007-05-04 2012-10-11 Bristol-Myers Squibb Company Agonistas [6,5]-bicíclicos de receptores GPR119 acoplados a la proteína G
PE20090449A1 (es) 2007-07-17 2009-04-18 Bristol Myers Squibb Co Agonistas de receptor acoplado a proteina g gpr119 de piridona
TW201006821A (en) 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
WO2011097079A1 (en) 2010-02-03 2011-08-11 Takeda Pharmaceutical Company Limited Apoptosis signal-regulating kinase 1 inhibitors
MX2012011460A (es) 2010-04-08 2012-11-23 Squibb Bristol Myers Co Analogos de pirimidinilpiperidiniloxipiridinona como moduladores de gpr119.
US8592396B2 (en) 2010-04-14 2013-11-26 Bristol-Myers Squibb Company Glucokinase activators and methods of using same
MX2012012902A (es) 2010-05-06 2012-12-17 Bristol Myers Squibb Co Analogos heteroarilo biciclicos como moduladores de receptor acoplado a la proteina g gpr119.
US8729084B2 (en) 2010-05-06 2014-05-20 Bristol-Myers Squibb Company Benzofuranyl analogues as GPR119 modulators
US9566269B2 (en) 2011-01-20 2017-02-14 Bionevia Pharmaceuticals Inc. Modified release compositions of epalrestat or a derivative thereof and methods for using the same
WO2013173198A1 (en) 2012-05-16 2013-11-21 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridone analogues as gpr119 modulators
WO2015061272A1 (en) 2013-10-22 2015-04-30 Bristol-Myers Squibb Company Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors
JP7072557B2 (ja) 2016-07-22 2022-05-20 ブリストル－マイヤーズ スクイブ カンパニー グルコキナーゼ活性化剤およびその使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4825448A (en) * 1986-08-07 1989-04-25 International Mobile Machines Corporation Subscriber unit for wireless digital telephone system
EP0343273B1 (de) * 1988-05-27 1994-04-27 Deutsche ITT Industries GmbH Korrekturschaltung für ein digitales Quadratur-Signalpaar
US5391551A (en) * 1993-05-10 1995-02-21 Pfizer Inc. Method of lowering blood lipid levels
US6107329A (en) * 1995-06-06 2000-08-22 Pfizer, Inc. Substituted n-(indole-2-carbonyl)-glycinamides and derivatives as glycogen phosphorylase inhibitors
US6297269B1 (en) * 1995-06-06 2001-10-02 Pfizer Inc. Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors

Also Published As

Publication number Publication date
YU30700A (sh) 2002-12-10
IS5453A (is) 2000-04-14
ES2161548T3 (es) 2001-12-01
NO20002164D0 (no) 2000-04-27
EA002365B1 (ru) 2002-04-25
GT199800166A (es) 2000-04-19
ATE205403T1 (de) 2001-09-15
DE69801680D1 (de) 2001-10-18
IL135713A0 (en) 2001-05-20
HUP0100272A3 (en) 2002-11-28
EP1032424B9 (en) 2004-10-06
UY25258A1 (es) 2000-12-29
CN1279617A (zh) 2001-01-10
JP2002504478A (ja) 2002-02-12
KR20010032304A (ko) 2001-04-16
AP9801401A0 (en) 1998-12-31
DZ2656A1 (fr) 2003-03-22
DE69801680T2 (de) 2002-02-07
AP911A (en) 2000-12-07
HRP20000327A2 (en) 2001-02-28
EP1032424B1 (en) 2001-09-12
PL340643A1 (en) 2001-02-12
AR016423A1 (es) 2001-07-04
MA26568A1 (fr) 2004-12-20
PA8462301A1 (es) 2000-05-24
BR9814698A (pt) 2000-10-03
WO1999026659A1 (en) 1999-06-03
KR20010032300A (ko) 2001-04-16
AU9555898A (en) 1999-06-15
EA200000433A1 (ru) 2000-12-25
ID24524A (id) 2000-07-20
CA2310069A1 (en) 1999-06-03
UA57811C2 (uk) 2003-07-15
ZA9810636B (en) 2000-05-22
OA11379A (en) 2004-01-28
PT1032424E (pt) 2001-12-28
BG104435A (bg) 2001-01-31
GR3037071T3 (en) 2002-01-31
EP1032424A1 (en) 2000-09-06
KR100661214B1 (ko) 2006-12-26
PE135399A1 (es) 2000-01-15
DK1032424T3 (da) 2001-11-19
TNSN98211A1 (fr) 2005-03-15
AU733304B2 (en) 2001-05-10
NO20002164L (no) 2000-07-19
HUP0100272A2 (hu) 2001-06-28
TR200001451T2 (tr) 2002-06-21

Similar Documents

Publication Publication Date Title
SK7222000A3 (en) Combination of an aldose reductase inhibitor and a glycogen phosphorylase inhibitor
US6297269B1 (en) Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
US5952322A (en) Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
JP3314938B2 (ja) グリコーゲンホスホリラーゼ抑制剤としての置換されたｎ−（インドール−２−カルボニル）−グリシンアミド類および誘導体
US6846820B2 (en) Substituted N-(indole-2-carbonyl) -amides and derivatives as glycogen phosphorylase inhibitors
EP1134213A2 (en) Process for the preparation of substituted N-(indole-2-carbonyl)- glycinamides
CZ20001837A3 (cs) Kombinace inhibitoru aldosa reduktasy a inhibitoru glykogen fosforylasy
MXPA00005025A (en) Combination of an aldose reductase inhibitor and a glycogen phosphorylase inhibitor